Literature DB >> 26851684

An in vivo model of anti-inflammatory activity of subdural dexamethasone following the spinal cord injury.

Jacek M Kwiecien1, Bozena Jarosz2, Wendy Oakden3, Michal Klapec4, Greg J Stanisz5, Kathleen H Delaney6, Edyta Kotlinska-Hasiec7, Rafal Janik8, Radoslaw Rola9, Wojciech Dabrowski10.   

Abstract

Current therapies to limit the neural tissue destruction following the spinal cord injury are not effective. Our recent studies indicate that the injury to the white matter of the spinal cord results in a severe inflammatory response where macrophages phagocytize damaged myelin and the fluid-filled cavity of injury extends in size with concurrent and irreversible destruction of the surrounding neural tissue over several months. We previously established that a high dose of 4mg/rat of dexamethasone administered for 1 week via subdural infusion remarkably lowers the numbers of infiltrating macrophages leaving large amounts of un-phagocytized myelin debris and therefore inhibits the severity of inflammation and related tissue destruction. But this dose was potently toxic to the rats. In the present study the lower doses of dexamethasone, 0.125-2.0mg, were administered via the subdural infusion for 2 weeks after an epidural balloon crush of the mid-thoracic spinal cord. The spinal cord cross-sections were analyzed histologically. Levels of dexamethasone used in the current study had no systemic toxic effect and limited phagocytosis of myelin debris by macrophages in the lesion cavity. The subdural infusion with 0.125-2.0mg dexamethasone over 2 week period did not eliminate the inflammatory process indicating the need for a longer period of infusion to do so. However, this treatment has probably lead to inhibition of the tissue destruction by the severe, prolonged inflammatory process.
Copyright © 2015 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Cavity of CNS injury; Inhibition of secondary inflammation; Phagocytosis of myelin debris; Spinal cord injury; Subdural infusion

Mesh:

Substances:

Year:  2015        PMID: 26851684     DOI: 10.1016/j.pjnns.2015.10.006

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  9 in total

1.  Effective improvement of the neuroprotective activity after spinal cord injury by synergistic effect of glucocorticoid with biodegradable amphipathic nanomicelles.

Authors:  YueLong Wang; Min Wu; Lei Gu; XiaoLing Li; Jun He; LiangXue Zhou; Aiping Tong; Juan Shi; HongYan Zhu; JianGuo Xu; Gang Guo
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  Local Serpin Treatment via Chitosan-Collagen Hydrogel after Spinal Cord Injury Reduces Tissue Damage and Improves Neurologic Function.

Authors:  Jacek M Kwiecien; Liqiang Zhang; Jordan R Yaron; Lauren N Schutz; Christian J Kwiecien-Delaney; Enkidia A Awo; Michelle Burgin; Wojciech Dabrowski; Alexandra R Lucas
Journal:  J Clin Med       Date:  2020-04-23       Impact factor: 4.241

Review 3.  Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury.

Authors:  Angela Faccendini; Barbara Vigani; Silvia Rossi; Giuseppina Sandri; Maria Cristina Bonferoni; Carla Marcella Caramella; Franca Ferrari
Journal:  Pharmaceuticals (Basel)       Date:  2017-07-05

4.  Prolonged inflammation leads to ongoing damage after spinal cord injury.

Authors:  Jacek M Kwiecien; Wojciech Dabrowski; Beata Dąbrowska-Bouta; Grzegorz Sulkowski; Wendy Oakden; Christian J Kwiecien-Delaney; Jordan R Yaron; Liqiang Zhang; Lauren Schutz; Barbara Marzec-Kotarska; Greg J Stanisz; John P Karis; Lidia Struzynska; Alexandra R Lucas
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

5.  The Role of Astrogliosis in Formation of the Syrinx in Spinal Cord Injury.

Authors:  Jacek M Kwiecien; Wojciech Dąbrowski; Jordan R Yaron; Liqiang Zhang; Kathleen H Delaney; Alexandra R Lucas
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 6.  Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury.

Authors:  Gang-Un Kim; Soo-Eun Sung; Kyung-Ku Kang; Joo-Hee Choi; Sijoon Lee; Minkyoung Sung; Seung Yun Yang; Seul-Ki Kim; Young In Kim; Ju-Hyeon Lim; Min-Soo Seo; Gun Woo Lee
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

7.  The Pathogenesis of Neurotrauma Indicates Targets for Neuroprotective Therapies.

Authors:  Jacek M Kwiecien
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 8.  Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice.

Authors:  Shawniqua Williams Roberson; Mayur B Patel; Wojciech Dabrowski; E Wesley Ely; Cezary Pakulski; Katarzyna Kotfis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 9.  Imaging of Neurotrauma in Acute and Chronic Settings.

Authors:  Shane Mallon; Jacek M Kwiecien; John P Karis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.